The National Pharmaceutical Pricing Authority (NPPA) approved a 30% cap on trade margins for 110 non-scheduled cancer drugs on October 8, 2026. This regulatory move aims to curb retail markups that currently reach up to 700%, potentially reducing patient costs by 20% to 70%. Investors are now tracking the expert committee's final list of affected drugs, due by October 14.
On October 8, 2026, India’s drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), approved a move to limit trade margins for 110 non-scheduled anti-cancer drugs. This regulation, which includes approximately 35 patented medicines, aims to bring down the high costs patients pay at hospitals and retail pharmacies. The government expects this intervention to save patients approximately ₹2,500 crore annually.
Curbing Retail Markups
The move addresses a significant issue in the Indian oncology market where trade margins—the profit added by distributors, retailers, and hospitals—have historically been very high. Data indicates that average markups for these non-scheduled drugs hover around 170%, with some extreme cases showing price gaps as wide as 700% between the procurement price and the final bill paid by the patient. By capping these margins at 30% of the Maximum Retail Price (MRP), the government intends to force a price correction ranging from 20% to 70% for the affected medications.
This policy is being implemented using powers under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, which allows the regulator to intervene in cases of public interest. The regulation applies to both domestic and imported formulations, covering a broad spectrum of branded and generic drugs.
Potential Risks and Market Impact
While the regulation aims to lower patient costs, it creates a shift in business dynamics for pharmaceutical distributors and hospital-attached pharmacies. These entities have traditionally relied on these higher margins, and the new 30% cap may pressure their profitability.
Another point for investors to consider is the risk of price manipulation. Manufacturers might be tempted to increase the base ex-factory price of drugs to offset the loss in trade margins. However, regulators often monitor such pricing adjustments to ensure the intent of the price reduction is not defeated. Additionally, for high-cost patented drugs, the price relief for patients may remain limited if the base manufacturing price remains high despite the margin cap.
What Investors Should Track Next
The financial impact on specific pharmaceutical companies remains uncertain until the final list of the 110 covered drugs is made public. An expert committee under the Directorate General of Health Services (DGHS) is currently finalizing this list. The official notification regarding the price caps is expected to follow after the committee submits its recommendations by October 14, 2026. Until that list is released, it is difficult to determine which specific firms or product portfolios will face the most direct impact on their distribution economics.